tirzepatide similar vs Ozempic: Key Differences Explained FDA Approves New Weight Loss

Cercato C, Fonseca FA

doi:10.1021/acs.jafc.1c03713

Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes

However, compounded tirzepatide pricing varies significantly between providersfrom $349 to $699 per month for the same medicationmaking it essential to understand what drives these differences and how to identify legitimate, affordable options